Cerity Partners LLC Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Cerity Partners LLC cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,361 shares of the company's stock after selling 8,376 shares during the quarter. Cerity Partners LLC's holdings in Neurocrine Biosciences were worth $3,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of NBIX. Nisa Investment Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 1,001.3% in the 1st quarter. Nisa Investment Advisors LLC now owns 14,042 shares of the company's stock valued at $1,553,000 after purchasing an additional 12,767 shares during the last quarter. Linden Thomas Advisory Services LLC increased its position in Neurocrine Biosciences by 4.0% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 6,603 shares of the company's stock worth $730,000 after purchasing an additional 253 shares during the period. Blackhawk Capital Partners LLC. grew its holdings in shares of Neurocrine Biosciences by 48.6% in the 1st quarter. Blackhawk Capital Partners LLC. now owns 14,521 shares of the company's stock worth $1,606,000 after acquiring an additional 4,750 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of Neurocrine Biosciences by 3.8% in the 1st quarter. Crossmark Global Holdings Inc. now owns 8,785 shares of the company's stock worth $972,000 after acquiring an additional 320 shares during the period. Finally, IFM Investors Pty Ltd grew its holdings in shares of Neurocrine Biosciences by 2.5% in the 1st quarter. IFM Investors Pty Ltd now owns 19,459 shares of the company's stock worth $2,242,000 after acquiring an additional 469 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 457 shares of the company's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the sale, the insider owned 4,730 shares in the company, valued at $638,550. This represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin Charles Gorman sold 9,613 shares of the company's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the transaction, the director directly owned 514,596 shares in the company, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,251 shares of company stock worth $14,978,602 over the last quarter. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Stock Up 0.5%

Shares of NASDAQ NBIX opened at $134.11 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98. The stock's 50 day moving average price is $125.18 and its 200-day moving average price is $121.53. The company has a market capitalization of $13.27 billion, a PE ratio of 45.46, a PEG ratio of 1.37 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same quarter in the previous year, the company earned $1.20 earnings per share. The business's quarterly revenue was up 11.1% on a year-over-year basis. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on NBIX. Needham & Company LLC raised their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 26th. HC Wainwright lowered their target price on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Wall Street Zen lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. Finally, Guggenheim upped their price objective on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.